Tadalafil and patients preference in the treatment of erectile dysfunction.
- Author:
Jian-lin HU
1
;
Bin CHEN
Author Information
1. Department of Urology, Shanghai Institute of Andrology, Renji Hospital, Shanghai Jiaotong University Medical School, Shanghai 200001, China.
- Publication Type:Journal Article
- MeSH:
Carbolines;
therapeutic use;
Erectile Dysfunction;
drug therapy;
psychology;
Humans;
Male;
Patient Satisfaction;
Phosphodiesterase Inhibitors;
therapeutic use;
Psychotherapy;
Tadalafil
- From:National Journal of Andrology
2006;12(12):1145-1148
- CountryChina
- Language:Chinese
-
Abstract:
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
